Strand Therapeutics key facts
as of Oct 2026- Developer of a medicine infrastructure platform intended to create medicines that respond to disease signals in real-time.
- Strand Therapeutics is valued at approximately $571.0M as of Oct 2026, set at its later-stage round, Aug 2025; nothing has traded since, per PrivateMarketView’s mark.
- It has raised $255.6M across 3 recorded rounds; the latest was Later Stage VC (Series B) ($153.0M) in Aug 2025.
- Notable investors include Creative Destruction Lab, MassChallenge, National Institutes of Health, Endless Frontier Labs, ANRI — 30 tracked in total.
- Strand Therapeutics has filed 2 Form Ds with the SEC since 2019, most recently Jul 2021 ($52.1M sold to 13 investors).
- Status: Privately Held (backing).
Valued at $571.0M at its later-stage round, Aug 2025. Nothing has traded since.
- ·The complete investor list: 30 names
- ·Watch Strand Therapeutics: the Monday email on marks, rounds and moves
Strand Therapeutics funding rounds
3 roundsWho backs Strand Therapeutics
30+Membership and data by Private Market View
Strand Therapeutics valuation
Strand Therapeutics was valued at $571 million at its later-stage round in Aug 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.
How much has Strand Therapeutics raised?
Strand Therapeutics has raised $256 million across 3 recorded rounds since 2019. The largest was a $5.9 million early-stage round in May 2019; the most recent was a $153 million Series B in Aug 2025.
Strand Therapeutics has filed 2 Form Ds with the SEC since 2019, most recently in Jul 2021 ($52.1 million sold to 13 investors).
Strand Therapeutics investors
30 investors are on record for Strand Therapeutics, including Creative Destruction Lab, MassChallenge, National Institutes of Health and Endless Frontier Labs. By type, the record holds 7 venture capital firms and 2 private equity firms. The Series B in Aug 2025 drew 13 investors.
Comparable companies
Comparable drug discovery names by valuation on PrivateMarketView: VeraDermics (NYS: MANE) ($596 million), Superluminal Medicines ($576 million) and Bambusa Therapeutics ($555 million).
About Strand Therapeutics
Developer of a medicine infrastructure platform intended to create medicines that respond to disease signals in real-time. The company's platform helps create programmable messenger ribonucleic acid therapies where synthetic biology meets programmable biology for logic-controlled expression, precision delivery, and control over therapeutic outcomes, enabling patients to have improved treatment options for cancer and other life-threatening diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2017
- Employees
- 119
- Website
- strandtx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.